VJHemOnc is committed to improving our service to you

VJVirtual | CLL outcomes after CD19 CAR-T with ibrutinib

VJHemOnc is committed to improving our service to you

Jordan Gauthier

Jordan Gauthier, MD, Fred Hutchinson Cancer Research Center, Seattle, WA, discussed the clinical outcomes of patients with chronic lymphocytic leukemia (CLL) with relapsed or refractory disease after CD19-specific CAR-T therapy used concurrently with ibrutinib. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

Share this video  

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter